Prostate Cancer Conference Highlights from ASCO GU 2025
Dana-Farber
March 03, 2025
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from GU ASCO 2025. Highlights in this video include:
• TALAPRO-2: Talazoparib + Enzalutamide improves OS in mCRPC with significant enrichment in HRR population
• ENZA-P: 177LuPSMA + Enzalutamide improves rPFS, OS and QOL in mCRPC
• WOLVERINE: Meta-analysis demonstrates benefit of metastasis-directed therapy in oligometastatic prostate cancer